Reddit Posts
Update on Regulatory Submission for Aducanumab in the European Union! COR588 (CRTX) may be approved in the European Union!
Cortexyme Stock: COR588 May Offer Some Hope To Investors (NASDAQ:CRTX)!
Cortexyme: Drug Candidate COR588 May Offer Some Hope To Investors
Potential Gamma. Yes CRTX is optionable. DD:
CRTX: We Still Have In Play Phase 1 Clinical Trial of COR588... We Are Waiting For The Results For Phase 1 of COR588! We might see again 50$ level!
CRTX: We Still Have In Play Phase 1 Clinical Trial of COR588... We Are Waiting For The Results For Phase 1 of COR588! We might see again 50$ level!
Part 2: Cortexyme (CRTX) and GAIN Clinical Trial: Is Alzheimer's Disease Solved?
Part 2: Cortexyme (CRTX) and GAIN Clinical Trial: Is Alzheimer's Disease Solved?
Part 2: Cortexyme (CRTX) and GAIN Clinical Trial: Is Alzheimer's Disease Solved?
Part 2: Cortexyme (CRTX) and GAIN Clinical Trial: Is Alzheimer's Disease Solved?
Part 2: Cortexyme (CRTX) and GAIN Clinical Trial: Is Alzheimer's Disease Solved?
Worksport Reports 2020 Full Year Financial Results and Provides Business Update ( WKSP ) (( $WKSP )) ((( just copied from emails i get from them )))
WKSP Why I’m long this penny for the EV market.
Close to Glory and Ripe for Ridicule
Mentions
WKSP has been doing great for me the last couple days. Sticking with it until at least $6 bucks. Way too many bots pumping it, but the data that I researched in it has been accurate on the website and articles I read that make the company look good long term & hit on it now short term while it catches up to what it should be valued at. Info - 📈 Financials: Revenue grew 10× (2023: $1.5M → 2025 guide: $20M) Gross margin doubled to 23%, aiming for 30% 🛠️ Product: SOLIS solar cover + COR 2.5 kWh battery launching this fall. Early beta units sold out. 🚚 Pilot fleet: 1,000-truck builder is paying to test. Success = larger rollout + fast lane to federal contracts. 📑 OEM path: ISO 9001 certified; MPPT tech works across voltages. Early engagement reported with Ford, GM, Hyundai. 🚀 Marketing: Chief of Chaos (ex-Uber creatives) running viral campaign. Big reach, small float = explosive setup. 📉 Risks: Pre-profit, limited cash, and the SOLIS ramp needs to hit timelines or dilution becomes a factor.
You’re so stupid Donakd! Stop saying THANK UOI COR YOUR ATTENTION TO THIS MATTER like some office manager
One other hurdle I forsee is that they're advertising that you can charge your truck with it, and get \~2,000 drive miles per year. That's actually like...pretty much nothing. I'm not sure your average consumer will be interested in an extra 5-10 miles per day of driving range. HOWEVER, the Solis cover with the COR battery pack is super interesting for contractors because then they can charge/power their tools at the work site without having to worry about draining the vehicle. I see huge potential in that, especially if they can partner with dealers/OEMs for easy purchasing/installation.
What’s the name of the company? COR doesn’t return anything on my end
Didn’t they just post an earnings that showed like 250 billion COR? Who gives a fuck about +0.9 onto that?
https://www.trade.gov//sites/default/files/2025-04/Preliminary_SummaryAnalysis_COR_March_2025.xlsx
Who's putting at least a bit of what they have liquid into small cap crypto so that when Trump mentions SOL/COR/XRP during his speech tonight they can catch the pump.
Have a look at the terms Dispersion and Correlation and then apply use of Index Correlation (COR1M, COR3M, etc CORxx) to your trading for better understanding of the relationship between the S&P + indiv stocks.
Is this bullish or bearish for a company? “Protective hairstyles include wigs, headwraps, and hairstyles such as individual braids, cornrows, locs, twists, Bantu knots, afros and afro puffs, and similar styles. The following states have already signed CROWN Act legislation…” $COR
Just the beginning! 2025 will be great. 2026-2027 are going to be amazing once production is rolling. I can see them forming a huge partnership with larger EV companies due to their patented technology. The word hasn’t even gotten out to be honest. They have improvements that could be made in PR and marketing so today they have fully launched is not even close to potential. I think we will see $3 in 2025 and $6-$10 in 2026-2027. Their 2025 projected internal revenue is 2x current market cap. Mind you, that is a conservative estimate. We haven’t even launched their bread and butter SOLID & COR solar panel cover which will make this thing go bananas
I love MVST! I remember the 1:1 price to sales days and wishing I bought in. Here’s another energy related company that will take off and is at that “low” wish I invested season of MVST and here is our opportunity: $WKSP Investors are about to flood in on $WKSP 🚀 Worksport produces truck accessories and has a unique patented designed where its truck tailgate covers are solar panels which expand vehicle range & provide additional battery systems for off the grid power. This patented designed had potential to garner huge contracts with Tesla, Ford, Chevrolet, Hyundai, etc as the EV and renewable energy market grows. Best part is - it appeals to EV and combustible engine vehicles. P/S is incredibly low, huge growth potential Once the SOLID & COR patented solar panels begin production, there will be huge interest and I am expecting partnerships with large automotive manufacturers. Now is the perfect time to buy and hold on for this giant. Buy yourself an early Christmas present and buy $WKSP today!
$WKSP Investors are about to flood in on $WKSP 🚀 Worksport produces truck accessories and has a unique patented designed where its truck tailgate covers are solar panels which expand vehicle range & provide additional battery systems for off the grid power. This patented designed had potential to garner huge contracts with Tesla, Ford, Chevrolet, Hyundai, etc as the EV and renewable energy market grows. Best part is - it appeals to EV and combustible engine vehicles. P/S is incredibly low, huge growth potential Once the SOLID & COR patented solar panels begin production, there will be huge interest and I am expecting partnerships with large automotive manufacturers. Now is the perfect time to buy and hold on for this giant. Buy yourself an early Christmas present and buy $WKSP today!
$WKSP Investors are about to flood in on $WKSP 🚀 Worksport produces truck accessories and has a unique patented designed where its truck tailgate covers are solar panels which expand vehicle range & provide additional battery systems for off the grid power. This patented designed had potential to garner huge contracts with Tesla, Ford, Chevrolet, Hyundai, etc as the EV and renewable energy market grows. Best part is - it appeals to EV and combustible engine vehicles. P/S is incredibly low, huge growth potential Once the SOLID & COR patented solar panels begin production, there will be huge interest and I am expecting partnerships with large automotive manufacturers. Now is the perfect time to buy and hold on for this giant. Buy yourself an early Christmas present and buy $WKSP today!
Worksport produces truck accessories and has a unique patented designed where its truck tailgate covers are solar panels which expand vehicle range & provide additional battery systems for off the grid power. This patented designed had potential to garner huge contracts with Tesla, Ford, Chevrolet, Hyundai, etc as the EV and renewable energy market grows. Best part is - it appeals to EV and combustible engine vehicles. P/S is incredibly low, huge growth potential Once the SOLID & COR patented solar panels begin production, there will be huge interest and I am expecting partnerships with large automotive manufacturers. Now is the perfect time to buy and hold on for this giant. Buy yourself an early Christmas present and buy $WKSP today!
[WKSP](https://worksport.com/pages/solis-cor)Worksport produces truck accessories and has a unique patented designed where its truck tailgate covers are solar panels which expand vehicle range & provide additional battery systems for off the grid power. This patented designed had potential to garner huge contracts with Tesla, Ford, Chevrolet, Hyundai, etc as the EV and renewable energy market grows. Best part is - it appeals to EV and combustible engine vehicles. P/S is incredibly low, huge growth potential Once the SOLID & COR patented solar panels begin production, there will be huge interest and I am expecting partnerships with large automotive manufacturers. Now is the perfect time to buy and hold on for this giant. Buy yourself an early Christmas present and buy $WKSP today!
$WKSP about to take off. Get in now before everyone’s talking about it in 1-2 months and you wish you did! I finally found one early and not late - so excited about this one. Investors are about to flood in on $WKSP 🚀 P/S is incredibly low, huge growth potential Once the SOLID & COR patented solar panels begin production, there will be huge interest and I am expecting partnerships with large automotive manufacturers. Now is the perfect time to buy and hold on for this giant. Buy yourself an early Christmas present and buy $WKSP today!
 $WKSP about to take off. Get in now before everyone’s talking about it in 1-2 months and you wish you did! I finally found one early and not late - so excited about this one. Investors are about to flood in on $WKSP 🚀 P/S is incredibly low, huge growth potential Once the SOLID & COR patented solar panels begin production, there will be huge interest and I am expecting partnerships with large automotive manufacturers. Now is the perfect time to buy and hold on for this giant. Buy yourself an early Christmas present and buy $WKSP today!
 Easy answer: $WKSP Order for 15,000 In for Market Open Monday! I finally found one early and not late - so excited about this one. Investors are about to flood in on $WKSP 🚀 P/S is incredibly low, huge growth potential Once the SOLID & COR patented solar panels begin production, there will be huge interest and I am expecting partnerships with large automotive manufacturers. Now is the perfect time to buy and hold on for this giant. Buy yourself an early Christmas present and buy $WKSP today!
https://preview.redd.it/fnxnj1gyot5e1.jpeg?width=1206&format=pjpg&auto=webp&s=7e940754c31bdefd05a5d461f1251251c2f3b338 Easy answer: $WKSP Order for 15,000 In for Market Open Monday! I finally found one early and not late - so excited about this one. Investors are about to flood in on $WKSP 🚀 P/S is incredibly low, huge growth potential Once the SOLID & COR patented solar panels begin production, there will be huge interest and I am expecting partnerships with large automotive manufacturers. Now is the perfect time to buy and hold on for this giant. Buy yourself an early Christmas present and buy $WKSP today!
The amount of difference in COR is bonkers. They are NOT THE SAME lmao
Closer you get to 59.5 the more that retirement account just looks like an account. I'd say pre-tax contributions are better than post-tax most often for most folks, like make some money on those differed taxes. That calculation is about how much you have and expect to make in retirement vs. how much you are making now, and if you're already maxing the pre-tax. You get that limit bumped up $7k to $30k for being 50. So the question is really one for a calculator. Like this one: https://www.aarp.org/work/retirement-planning/roth_vs_traditional_401k_calculator.html?cmp=KNC-DSO-COR-Core-Retirement-NonBrand-Exact-35114-GOOG-RETIREMENT-Rothvs.Traditional401(K)Calculator-Exact-NonBrand When you drop down to part time, or your income drops, then it might pay to slide a little into the Roth, but that depends on your overall picture for that year vs. the dreaded RMD at 72. Personally, if I do well enough that I pay a little more in taxes when I'm 72 than I do now, that is not a bad problem to have. Slightly sub-optimal, but patriotic.
Implied correlations were 82% today via the CBOE COR1M index. Surpassing the september selloff and halfway to the july/august sell off. Bad news bulls for the US equity market.
[here’s 50 years of $500 a month invested at 6%](https://www.aarp.org/money/investing/investment_return_calculator/?cmp=KNC-DSO-COR-Core-Money-NonBrand-Phrase-30830-GOOG-MONY-InvestmentReturnsCalculator-Phrase-NonBrand&gad_source=1&gbraid=0AAAAAD5P0D88JjSLeJgeutX1yAX_azB8m&gclid=EAIaIQobChMIyovD0rjxiAMVhCCtBh2phRqlEAAYASAAEgJJUPD_BwE&gclsrc=aw.ds) [here’s $100k with no additional, for 50 years at 6%](https://www.aarp.org/money/investing/investment_return_calculator/?cmp=KNC-DSO-COR-Core-Money-NonBrand-Phrase-30830-GOOG-MONY-InvestmentReturnsCalculator-Phrase-NonBrand&gad_source=1&gbraid=0AAAAAD5P0D88JjSLeJgeutX1yAX_azB8m&gclid=EAIaIQobChMIyovD0rjxiAMVhCCtBh2phRqlEAAYASAAEgJJUPD_BwE&gclsrc=aw.ds) So yeah eventually the $500 can be better, but it can take a really long while.
COR1M is straight up staring you in the face telling you markets are going lower the rest of the week
VIX,VOLI,COR1M,VVIX moving averages, RVI, and price all trending down and I thought selling calls was a good idea. Actually I didnt think at all I just did, and I payed the price.
VIX,VOLI,VVIX,COR1M all trending down and im selling calls and leveraged short like a full regard. Sometimes my own stupidity baffles me. Of course if we get the big sell off today I was hoping for ill feel like a genius but because of that, it wont happen. Massive short squeez to end the week and once my losses are realized the market will dump. Just as it was written.
Thanks, knew about COR1M because you mentioned it before, and I just found out about VVIX yesterday.
Dont have a favorite I look at a basket of vol products and wait for confirmation on all of them before entering trades. I use VIX, VVIX, VIX1D, VOLI, SKEW, and COR1M. i use them in tandem and some for particular trades, like my arb trade this afternoon using VIX1D and SPX 0DTE iv.
Big fat shrek cocks. (I hope. I see lots of mixed signals in VIX, VOLI, and COR1M and I dont see any defined trend for today as of yet)
COR1M/RVI negative divergence. We will see a pause in the sell off if not tomorrow or friday than monday and tuesday. With Vix of 18 selling puts is a very attractive trade for the short term.
Its got more to go for one, and for two, we had a full week to find an entry after last weeks selloff. The writing was on the wall and I repeatedly called for it. VIX, COR1M, SKEW, were all screaming to get short. Also, call buyers have been buying ath for over a year now and making money. It pays to follow the trend. Buy low sell high is bullshit advice and why most traders fail. You trade the breakout and buy high sell higher, or sell low and buy back lower.
I give tomorrows chance of down vs up at 80/20 based on VIX, PCC, and COR1M
C. Rotation into small caps at large caps expense, until credit spreads widen signaling stress in the economy. The feds master plan of a forced recession like every other cycle in the history of our country plays out. Correlations as measured by COR1M spike and everything sells off as investors flood into safe haven bonds. Bulls capitulate and turn to bears at the bottom because greed turns to fear, they pull a cathy and sell at a loss. Bears who were patient when everyone called them wrong and dumb, get greedy and buy the bottom just like papa Buffet taught them.
According to my Ber gauge (CBOE COR1M) theres no real sign of panick yet and the sell of in tech is just a rotation trade. One that I predicted and made sweet sweet tendies on my XLV, XLU, XLF calls.
Implied Correlation, a gauge of herd behavior, is the market’s expectation of future diversification benefits. It measures the average expected correlation between the top 50 stocks in the SPX index. Cboe calculates COR3M by using ATM delta relative constant maturity SPX index and component option implied volatilities. Positive correlation spikes indicate lower expected diversification benefits, increased systematic risk, and a higher likelihood of experiencing extreme tail events associated with sudden market movements.
If you want to short SPY or QQQ, look up COR1M on your charting platform. When that starts to rise is when you want to get short. Otherwise you are throwing good money at bad.
My 2 cents: Currently only a few companies drive the S&P500, the correlation index COR3M is extremely low with 7.79. So, as soon as there is any doubt that the performance of these few drivers is unfounded, people will start selling off (who would like to go from +800% to +200% on NVDA?) and this could lead to a significant drop.
I am looking at correlations, specifically spx vs its top 50 underlyings as measure by COR1M, VIX vs SPX, and as you mentioned, defensives vs SPX. I noticed last friday XLV saw a good inflow and bought july/august monthly calls. Also bought calls on XLU after we saw yields spike a couple weeks ago likely from japan selling
SPX/NDX short term trading Before opening any positions, go through this checklist thoroughly and document all aspects. Using a few key indicators and fundamentals to approach the market will give an edge that has multiple supporting facts. [ ] Is volatility as measured by VIX/VVIX rising or falling and on what time frame? Is it at or near key support or resistance levels? [ ] Is IVR rising or falling and is it above or below 30? [ ] Are correlations rising or falling as measured by COR1M ? [ ] Is there liquidity being pulled or added to the market as measured by DXY, Reverse repo, and bond spreads? [ ] What does the chart look like for SPX/NDX? Is there overbought or oversold conditions present? Is it in a range or trending? What is the short term trend and what is the longer term trend? [ ] Is there dealer/MM gamma bias and if not, where is the gamma flip? [ ] Where are the high volume option levels where prices will be attracted to? After answering all of these questions formulate a trading plan for your given time frame. Do all of these answers make sense for a directional trade or a neutral trade? For a short option or a long option? Where is your price target/range and when will you get out of the trade if you are right and where will you get out if you are wrong?
Interesting. We'll see how it plays out. Q1 already saw a lower COR than prior quarters, but revenue dipped too. Financials are not pretty. But we'll see how their cost cutting + this investment pushes them.
Nah. They are taking a short against a company that's losing money on a consistent basis. If it wasn't for Texas paying them, they would have been like COR and bankrupt already. RIOT still needs to sell out a certain amount of BTC to get some revenue. Holding it doesn't do much for them. The drop in rates recently is taking the pressure off, but rates won't go back to previous lows that will be needed to keep this afloat. If Texas backs out of paying them, they are toast. I think it will happen sooner than later.
Short Idea - COR - Data stolen in breach. [https://techcrunch.com/2024/05/24/cencora-americans-health-data-stolen-breach-cyberattack/?guccounter=1](https://techcrunch.com/2024/05/24/cencora-americans-health-data-stolen-breach-cyberattack/?guccounter=1)
Their COR is fine but they certainly have an operating expense and debt issue. They would have to cut R&D in half around $500M a year, grow revenue and it would still take 3 years to break even on equity. That’s assuming they take on no new debt. I don’t see it personally.
Since my last post I've decided to decrease my portfolio to under 10 companies, only keeping the ones I've spent the most time researching and following. |Name|Market Cap|Weight|Description| |:-|:-|:-|:-| |ESGV||15.9%|US ETF| |Clínica Baviera (CBAV)|$421.7M|10.1%|Spanish eye clinic operator (largest in Europe)| |Mytilineos (MYH)|$5.19B|10.0%|Vertically integrated Greek utility & aluminum producer (largest in Europe)| |Jerónimo Martins (JMT)|$15.5B|9.9%|Vertically integrated Portuguese grocery co (largest in Portugal & Poland)| |cottaLTD (3359)|$33.76M|9.7%|Japanese baking materials co| |Corticeira Amorim (COR)|$1.43B|9.6%|Largest cork company in the world, with massive moat.| |Van de Velde (VAN)|$460.74M|9.3%|Belgian lingerie company| |Bank of Greenland (GRLA)|$175.6M|9.2%|Largest bank in Greenland.| |Eiffage (FGR)|$10.5B|9.1%|French infrastructure company| |MÁDARA Cosmetics (MDARA)|$55.6M|7.3%|Latvian cosmetics company| Sectors: Materials (19.6%), Cons Staples (18%), Healthcare (12.3%), Financials (11.4%), Cons Dis (11.4%), Industrials (10.2%), Utilities (10%), Tech (5.1%), Comms (1.6%), Real Estate (0.4%), Energy (0%) Cap: Large (31%), Mid (12.7%), Small (56.3%)
Dear OP, you're asking about a fund rating system called LIPPER RATING I wasn't aware of it so I googled a few resources and summarised for myself/for you. I like to review so forgive me if you know this...helps me analyse I'm grateful to have the insight now I wasn't aware Lipper isn't perfect so I feel a need to review & compare other rating systems side by side for myself offline. [Investopedia](https://www.investopedia.com/articles/investing/091015/lipper-rating-system-explained.asp) : Lipper rating explained Lipper is a research tool, contains Lipper rating score, Lipper Average & Lipper Index Tool rates both domestic (USA funds) & international (non USA funds) Tool does rate financial fund products using both - 1. fund capitalisation & - 2. the funds style (various characteristics & a Lipper Z-score) Lipper Methodology : [6 assessment methods](https://fastercapital.co/i/Beyond-Traditional-Returns--Lipper-Leader-and-Risk-Adjusted-Performance--Unveiling-the-Methodology-Behind-Lipper-Leader-Ratings.webp) - 1 A holistic evaluation - 2 Consistency - 3 Preservation - 4 Expense Ratio (& Tax Efficiency) - 5 Options comparison - 6 the Best Option Lipper rating is an alternative to other rating systems (Morningstar's, Standard & Poor's) Lipper Rating score is 5 tiered : 1(lowest) to 5 (highest Lipper rating) - if you have 100 funds scored : each output tier would represent 20% of the input 100 Lipper rating only applies to one classification type eg a bond ETF for the preservation of capital (POC) class (not the consistency of return (COR) class). Lipper Leader refers to best of POC or best of COR. Other classes available. [see How Lipper Leader works](https://www.investopedia.com/terms/l/lipper-leader.asp) Drawbacks : Lipper rating has drawbacks - eg rating is a function of number of funds being examined (eg the 20% applied to X funds & X increases) - funds get rating amended without doing anything better or worse). - fund rating can't be compared year to year without a deeper understanding of factors (eg how many funds were assessed in that year that category) Hope it helps
https://www.indeed.com/m/jobs?q=&l=Chicago%2C%20IL&radius=35&jlid=402d6ad50e16c894&rbl=Chicago%2C%20IL&sc=0kf%3Aattr%28CF3CP%29attr%28FCGTU%7CHFDVW%7CQJZM9%7CUTPWG%252COR%29explvl%28ENTRY_LEVEL%29%3B&from=so, https://www.indeed.com/m/jobs?q=&l=Seattle%2C%20WA&radius=35&jlid=1e8a7dce52945215&rbl=Seattle%2C%20WA&sc=0kf%3Aattr%28CF3CP%29attr%28FCGTU%7CHFDVW%7CQJZM9%7CUTPWG%252COR%29explvl%28ENTRY_LEVEL%29%3B&from=so
Rebalanced my portfolio for 2022, got rid of EM. ISH COR S&P500 U.ETF USD(ACC) 40,4% ISHAR.VII ISH.NASD.100 UC.ETF 19,2% BLK 14.1% Aapl 14% ASML 12.3%
Hello? A shelf offering is a SEC provision that allows an company issuer **to register a new issue of securities without having to sell the entire issue at once**. The issuer **can instead sell portions of the issue over a three-year period without re-registering the security or incurring penalties**. Cortexyme can't confirm when they will sell shares at the market, even they don't know which will be the price at that time and the volume of the offerings. It can be in the summer at 60$ x 2,500,000 shares (After publishing Phase 1 results for COR588). It can be in the spring at 40$ x 3,750,000 shares (After biotechs run). It can be in the autumn at 100$ x 1,500,000 shares. Cortexyme can do it through trances, to sell $150,000,000 in shares between second half of 2022 and first half of 2023 at the price range $50-$200.
The start of "GAIN2 TRIAL" and the results for phase 1 - "COR588".
Yes but even like a level 1 EM should be taking in a lot more than that. Im fully remote. Like work from a Mexican beach remote. Levels.fyi And I’m familiar with government contractors too because I was briefly a green suit COR
comment from our private board on ST: Covid looks very good so far. The early numbers are way better than competition. See PFE's drug: "PF-07321332 inhibited SARS-CoV-2 replication as assessed using a nanoluciferase reporter virus in A549-ACE2 cells with EC50 and EC90 values of 77.9 nM and 215 nM respectively, with no cytotoxicity detected at concentrations up to 3 μM ..." (the list goes on, these are a bit different for each cell type / culture...) https://www.science.org/doi/10.1126/science.abl4784 COR803 beats these numbers by a factor of 5 or more. I think this is a really nice demonstration of their chemistry expertise in this particular area.
Have you seen the updated preso on the IR section of their website? Pretty bullish on COR803, along with some updates on GAIN2 and a few new "unidentified" indications. https://ir.cortexyme.com/static-files/a070a162-4594-4f0f-baba-de00bf9af639
Here is the most basic DD on CRTX. I shared this a few days ago and have been reusing it whenever someone asks about it or implies they’re curious about knowing more. Cheers! Cortexyme (CRTX) is a clinical stage biopharmaceutical focused on developing treatments for degenerative diseases, most notably Alzheimer’s. The firms most noteworthy treatment within its pipeline is Atuzaginstat (COR388). Atuzaginstat is a small molecule inhibitor that targets a bacteria, *P. gingivalis*, that some believe is partially responsible for the development of Alzheimer’s disease and other forms of cognitive impairment. Over the past year CRTX rose to a high of $120 in stock price largely due to Atuzaginstat’s forward progress in drug trials. Then in October, the stock fell a whopping 86%. The decline in price was a result of Atuzaginstat missing key goals in an important trial. Specifically, the drug worked well in patients who had *P. gingivalis* present in their saliva but not as well as the firm had hoped for general patients. Believing the key driver of the firm’s expected value, investors sold and shorts piled on. Despite the fact that key results in the trial failed, the firm still boasts a robust pipeline. Biopharmaceutical firms are unique in the sense that their value is not relegated to solely their financial position, but the expected value should they be successful in producing a drug. Given CRTX’s current pipeline, I personally believe that the firm is undervalued and that the 86% decline in price was overly excessive. Given a relatively stable price over the past few months, a small float of 18 million shares, and 9 million of those shares currently being held short (50% short interest) I believe that if the stock continues its recent increase in volume and upward movement there could be rapid price acceleration, bringing the stock to previously held levels (around $20 to $30s) in the short term. Obviously, nothing is guaranteed and none of what I have espoused should be taken as financial advice but I am bullish on CRTX and think it could be of interest to others here. Cheers! TLDR: CRTX is a biopharmaceutical firm that dropped a ton due to a trial misstep and now has 50% short interest with a small float. Stock has been picking up steam because some believe it is undervalued. Could go to the moon. Cue the rocket emojis. Link to CRTX Pipeline info: [https://www.cortexyme.com/pipeline/](https://www.cortexyme.com/pipeline/)
CRTX!! Basic DD: Cortexyme (CRTX) is a clinical stage biopharmaceutical focused on developing treatments for degenerative diseases, most notably Alzheimer’s. The firms most noteworthy treatment within its pipeline is Atuzaginstat (COR388). Atuzaginstat is a small molecule inhibitor that targets a bacteria, P. gingivalis, that some believe is partially responsible for the development of Alzheimer’s disease and other forms of cognitive impairment. Over the past year CRTX rose to a high of $120 in stock price largely due to Atuzaginstat’s forward progress in drug trials. Then in October, the stock fell a whopping 86%. The decline in price was a result of Atuzaginstat missing key goals in an important trial. Specifically, the drug worked well in patients who had P. gingivalis present in their saliva but not as well as the firm had hoped for general patients. Believing the key driver of the firm’s expected value, investors sold and shorts piled on. Despite, key results in the trial having failed, the firm still boasts a robust pipeline. Biopharmaceutical firms are unique in the sense that their value is not relegated to solely their financial position, but the expected value should they be successful in producing a drug. Given CRTX’s current pipeline, I personally believe that the firm is undervalued and that the 86% decline in price was overly excessive. Given a relatively stable price over the past few months, a small float of 18 million shares, and 9 million of those shares currently being held short (50% short interest) I believe that if the stock continues its recent increase in volume and upward movement there could be rapid price acceleration, bringing the stock to previously held levels (around $20 to $30s) in the short term. Obviously, nothing is guaranteed and none of what I have espoused should be taken as financial advice but I am bullish on CRTX and think it could be of interest to others here. Cheers! TLDR: CRTX is a biopharmaceutical firm that dropped a ton due to a trial misstep and now has 50% short interest with a small float. Stock has been picking up steam because some believe it is undervalued. Could go to the moon. Cue the rocket emojis. Link to CRTX Pipeline info: https://www.cortexyme.com/pipeline/
So just recently they moved COR388 back on their website. It’s believed management is in discussions with the fda to establish a path forward with new trials that are specified the measure the effect on the more limited market audience and that the plan could be announced this month or next.
CRTX (Cortexyme). Here’s the basic DD: Cortexyme (CRTX) is a clinical stage biopharmaceutical focused on developing treatments for degenerative diseases, most notably Alzheimer’s. The firms most noteworthy treatment within its pipeline is Atuzaginstat (COR388). Atuzaginstat is a small molecule inhibitor that targets a bacteria, P. gingivalis, that some believe is partially responsible for the development of Alzheimer’s disease and other forms of cognitive impairment. Over the past year CRTX rose to a high of $120 in stock price largely due to Atuzaginstat’s forward progress in drug trials. Then in October, the stock fell a whopping 86%. The decline in price was a result of Atuzaginstat missing key goals in an important trial. Specifically, the drug worked well in patients who had P. gingivalis present in their saliva but not as well as the firm had hoped for general patients. Believing the key driver of the firm’s expected value, investors sold and shorts piled on. Despite the fact that key results in the trial failed, the firm still boasts a robust pipeline. Biopharmaceutical firms are unique in the sense that their value is not relegated to solely their financial position, but the expected value should they be successful in producing a drug. Given CRTX’s current pipeline, I personally believe that the firm is undervalued and that the 86% decline in price was overly excessive. Given a relatively stable price over the past few months, a small float of 18 million shares, and 9 million of those shares currently being held short (50% short interest) I believe that if the stock continues its recent increase in volume and upward movement there could be rapid price acceleration, bringing the stock to previously held levels (around $20 to $30s) in the short term. Obviously, nothing is guaranteed and none of what I have espoused should be taken as financial advice but I am bullish on CRTX and think it could be of interest to others here. Cheers! TLDR: CRTX is a biopharmaceutical firm that dropped a ton due to a trial misstep and now has 50% short interest with a small float. Stock has been picking up steam because some believe it is undervalued. Could go to the moon. Cue the rocket emojis. Link to CRTX Pipeline info: https://www.cortexyme.com/pipeline/
CRTX Basic DD: Cortexyme (CRTX) is a clinical stage biopharmaceutical focused on developing treatments for degenerative diseases, most notably Alzheimer’s. The firms most noteworthy treatment within its pipeline is Atuzaginstat (COR388). Atuzaginstat is a small molecule inhibitor that targets a bacteria, *P. gingivalis*, that some believe is partially responsible for the development of Alzheimer’s disease and other forms of cognitive impairment. Over the past year CRTX rose to a high of $120 in stock price largely due to Atuzaginstat’s forward progress in drug trials. Then in October, the stock fell a whopping 86%. The decline in price was a result of Atuzaginstat missing key goals in an important trial. Specifically, the drug worked well in patients who had *P. gingivalis* present in their saliva but not as well as the firm had hoped for general patients. Believing the key driver of the firm’s expected value, investors sold and shorts piled on. Despite, key results in the trial having failed, the firm still boasts a robust pipeline. Biopharmaceutical firms are unique in the sense that their value is not relegated to solely their financial position, but the expected value should they be successful in producing a drug. Given CRTX’s current pipeline, I personally believe that the firm is undervalued and that the 86% decline in price was overly excessive. Given a relatively stable price over the past few months, a small float of 18 million shares, and 9 million of those shares currently being held short (50% short interest) I believe that if the stock continues its recent increase in volume and upward movement there could be rapid price acceleration, bringing the stock to previously held levels (around $20 to $30s) in the short term. Obviously, nothing is guaranteed and none of what I have espoused should be taken as financial advice but I am bullish on CRTX and think it could be of interest to others here. Cheers! TLDR: CRTX is a biopharmaceutical firm that dropped a ton due to a trial misstep and now has 50% short interest with a small float. Stock has been picking up steam because some believe it is undervalued. Could go to the moon. Cue the rocket emojis. ​ Link to CRTX Pipeline info: [https://www.cortexyme.com/pipeline/](https://www.cortexyme.com/pipeline/)
I shared this here a few days ago - but it didn’t garner too much notice. Here’s the basic DD and the basis for the significant drop in price that occurred. Cortexyme (CRTX) is a clinical stage biopharmaceutical focused on developing treatments for degenerative diseases, most notably Alzheimer’s. The firms most noteworthy treatment within its pipeline is Atuzaginstat (COR388). Atuzaginstat is a small molecule inhibitor that targets a bacteria, P. gingivalis, that some believe is partially responsible for the development of Alzheimer’s disease and other forms of cognitive impairment. Over the past year CRTX rose to a high of $120 in stock price largely due to Atuzaginstat’s forward progress in drug trials. Then in October, the stock fell a whopping 86%. The decline in price was a result of Atuzaginstat missing key goals in an important trial. Specifically, the drug worked well in patients who had P. gingivalis present in their saliva but not as well as the firm had hoped for general patients. Believing the key driver of the firm’s expected value, investors sold and shorts piled on. Despite, key results in the trial having failed, the firm still boasts a robust pipeline. Biopharmaceutical firms are unique in the sense that their value is not relegated to solely their financial position, but the expected value should they be successful in producing a drug. Given CRTX’s current pipeline, I personally believe that the firm is undervalued and that the 86% decline in price was overly excessive. Given a relatively stable price over the past few months, a small float of 18 million shares, and 9 million of those shares currently being held short (50% short interest) I believe that if the stock continues its recent increase in volume and upward movement there could be rapid price acceleration, bringing the stock to previously held levels (around $20 to $30s) in the short term. Obviously, nothing is guaranteed and none of what I have espoused should be taken as financial advice but I am bullish on CRTX and think it could be of interest to others here. Cheers! TLDR: CRTX is a biopharmaceutical firm that dropped a ton due to a trial misstep and now has 50% short interest with a small float. Stock has been picking up steam because some believe it is undervalued. Could go to the moon. Cue the rocket emojis. Link to CRTX Pipeline info: https://www.cortexyme.com/pipeline/
The Bullish Case for CRTX (Cortexyme) I shared this here a few days ago - but it didn’t garner too much notice. Here’s the basic DD and the basis for the significant drop in price that occurred. Cortexyme (CRTX) is a clinical stage biopharmaceutical focused on developing treatments for degenerative diseases, most notably Alzheimer’s. The firms most noteworthy treatment within its pipeline is Atuzaginstat (COR388). Atuzaginstat is a small molecule inhibitor that targets a bacteria, *P. gingivalis*, that some believe is partially responsible for the development of Alzheimer’s disease and other forms of cognitive impairment. Over the past year CRTX rose to a high of $120 in stock price largely due to Atuzaginstat’s forward progress in drug trials. Then in October, the stock fell a whopping 86%. The decline in price was a result of Atuzaginstat missing key goals in an important trial. Specifically, the drug worked well in patients who had *P. gingivalis* present in their saliva but not as well as the firm had hoped for general patients. Believing the key driver of the firm’s expected value, investors sold and shorts piled on. Despite, key results in the trial having failed, the firm still boasts a robust pipeline. Biopharmaceutical firms are unique in the sense that their value is not relegated to solely their financial position, but the expected value should they be successful in producing a drug. Given CRTX’s current pipeline, I personally believe that the firm is undervalued and that the 86% decline in price was overly excessive. Given a relatively stable price over the past few months, a small float of 18 million shares, and 9 million of those shares currently being held short (50% short interest) I believe that if the stock continues its recent increase in volume and upward movement there could be rapid price acceleration, bringing the stock to previously held levels (around $20 to $30s) in the short term. Obviously, nothing is guaranteed and none of what I have espoused should be taken as financial advice but I am bullish on CRTX and think it could be of interest to others here. Cheers! TLDR: CRTX is a biopharmaceutical firm that dropped a ton due to a trial misstep and now has 50% short interest with a small float. Stock has been picking up steam because some believe it is undervalued. Could go to the moon. Cue the rocket emojis. Link to CRTX Pipeline info: [https://www.cortexyme.com/pipeline/](https://www.cortexyme.com/pipeline/)
I posted this a while back: The Bullish Case for CRTX (Cortexyme) Cortexyme (CRTX) is a clinical stage biopharmaceutical focused on developing treatments for degenerative diseases, most notably Alzheimer’s. The firms most noteworthy treatment within its pipeline is Atuzaginstat (COR388). Atuzaginstat is a small molecule inhibitor that targets a bacteria, *P. gingivalis*, that some believe is partially responsible for the development of Alzheimer’s disease and other forms of cognitive impairment. Over the past year CRTX rose to a high of $120 in stock price largely due to Atuzaginstat’s forward progress in drug trials. Then in October, the stock fell a whopping 86%. The decline in price was a result of Atuzaginstat missing key goals in an important trial. Specifically, the drug worked well in patients who had *P. gingivalis* present in their saliva but not as well as the firm had hoped for general patients. Believing the key driver of the firm’s expected value, investors sold and shorts piled on. Despite the fact that key results in the trial failed, the firm still boasts a robust pipeline. Biopharmaceutical firms are unique in the sense that their value is not relegated to solely their financial position, but the expected value should they be successful in producing a drug. Given CRTX’s current pipeline, I personally believe that the firm is undervalued and that the 86% decline in price was overly excessive. Given a relatively stable price over the past few months, a small float of 18 million shares, and 9 million of those shares currently being held short (50% short interest) I believe that if the stock continues its recent increase in volume and upward movement there could be rapid price acceleration, bringing the stock to previously held levels (around $20 to $30s) in the short term. Obviously, nothing is guaranteed and none of what I have espoused should be taken as financial advice but I am bullish on CRTX and think it could be of interest to others here. Cheers! TLDR: CRTX is a biopharmaceutical firm that dropped a ton due to a trial misstep and now has 50% short interest with a small float. Stock has been picking up steam because some believe it is undervalued. Could go to the moon. Cue the rocket emojis. Link to CRTX Pipeline info: [https://www.cortexyme.com/pipeline/](https://www.cortexyme.com/pipeline/)
Lmao, see I have actually done actual DD. The firm has enough cash on hand to continue operations well into 2023. COR388 didn’t fail, it just didn’t hit key metrics the firm had hopped for. Trial participants who had P. gingivales present in Salvia still have positive results that were statistically significant. Even with a reduced potential market share usage the drug has potential for Alzheimer’s patients and the firm is expected to receive approval for further stages related to COR388’s application to other degenerative diseases such as Parkinson’s. Casey Lynch doesn’t have her head up her as. Is she the god send of CEOs, no, but she’s experienced and has a history of having produced various bio pharmaceutical firms some successful, some not. You haven’t presented a real bear thesis you just backed up statements with hot air. I’ve actually done my DD well before I decided to comment. The bear thesis you’ve presented is based on technicals and you’ve added nothing of significant substance here.
Research scientist that I converse with wrote a seeking alpha article on them a few months ago. He met them at AAIC and was recruited to help on COR803 with animal resources. Don't count them out on Covid, could be substantial, word of IND might propel us
You're gonna have to put me down for some shares of $COR
So you are both a spammer and a liar? There will be no FDA approval by 11/11/21 -/ the company has not even started Phase 3 trials and Phase 2 of COR388 had disappointing results which is why the drop in value.
The trial you refer to is 1.) only looking at Periodontal according to the HC Wainwright call with VOO Chris Lowe. It's a MAD / SAD study 2.) Same Drug essentially but different pharmacokinetics billed as a 2nd Gen Lysine target (once a day COR588 vs twice daily COR388) Don't think there's too much to draw from it besides periodontal is likely positive in REPAIR (the subset in GAIN. Periodontal also looked good from their animal studies). The fact that they went ahead with COR388 for a larger trial in Parkinson's Disease (PEAK) does make me feel bullish. The same person could look and say maybe they're throwing darts at a board. Neuro degenerative studies are expensive + require great oversight (CRO, DSMB, FDA). No one will know data results until they read out but - even if it is only beneficial in APOE 4 (65% of GAIN trial) would be immensely beneficial and a huge potential market cap. AD is a grave yard. It's a long shot, but it's a unique MOA, they have shown that at least it's possible to induce AD with P gingivalis in mice, so maybe a subset of patients for AD may see benefit. I could go into more detail, but I think they have something (even if trial doesn't reach primary endpoint). They focus on 'upstream' AD in their talks, studies, etc. From this it means that it likely won't 'cure' damage already done, but would prevent rapid worsening (sort of like a disease control, like MS). This would mean chronic (take this medication forever), that would be huge. Or maybe it provides some benefit, but they need a combination (arginine based inhibitor + lysine based inhibitor) to maximize control. I'm just waiting, and am in no rush. Theoretically their trajectory if they hit would be insane (20B short term, 100BN with a couple years). So I'm willing to take that risk that some, but not all, AD patients may benefit from their drug. If it misses this stock crashes, if it hits its going to really hit. We'll know by 11/11, maybe sooner. I look at it as a lottery ticket, because that's what it is, and I am very comfortable losing the money I have in it. Best of luck with your investments, Dr. DD
He’s really smart and I like his stuff. He mentioned before he liked the stock when it was in the 40/50 range but but not recently near 100 if I recall correctly. So a lot of the missing data he referenced is actually here: https://www.cortexyme.com/wp-content/uploads/2019/04/A-Randomized-Placebo-Controlled-Repeat-Dose-Phase-1-Study-of-COR388-in-Older-Healthy-Volunteers-and-Patients-With-Alzheimer%E2%80%99s-Disease.pdf He’s right you can’t get a lot of significance, but there is some, and if you did an aggregated analysis of the endpoints, you’d 100% get good significance. The statistical question is - what’s the chance this is noise, but the comprehensive outcomes across all the tests. I’ve not run it, but can tell you it’s there. But yes, small sample so real chance there’s strong omitted specifics bias per subject that wasn’t caught here and is idiosyncratic and boosted results.
I have two other things to add: 1 - They are already initiating Phase 1 trials on a modified molecule, still targeting Lysine, for once a day administration. #Why would they initiate a new trial on a drug that didn't work? https://www.businesswire.com/news/home/20210908005279/en/Cortexyme-Expands-Proprietary-Development-Pipeline-with-Initiation-of-Phase-1-Clinical-Trial-of-COR588 Oh, and they are working towards trials on Arginine gingipain inhibitors as well. https://www.businesswire.com/news/home/20210908005279/en/Cortexyme-Expands-Proprietary-Development-Pipeline-with-Initiation-of-Phase-1-Clinical-Trial-of-COR588 2 - CRTX is currently hiring for a Senior Vice President, Commercial to forge a path to commercial manufacturing and distribution. You would only hire for this role if you expected to go into production. https://www.cortexyme.com/career-senior-vice-president-commercial/ .... Positions: I own 1000 shares, and had sold covered calls on them back when it was at $90. I closed those calls around $70. I also sold some December $15p as I would be very surprised if this went much below $15 simply because they have about $5 of cash on hand per share, and nearly zero debt. IMO, last week was de-hedging, and fear that someone knew something. This is an _extremely_ illiquid stock, so if you do buy, use limit orders. Anyone selling naked calls on this are taking a _massive_ risk.
crypto isn't a hedge against anything. It is pure speculation. Gold isn't a great inflation hedge. I personally like REITs as an inflation hedge. My STAG, LSI, WPC, and COR have been doing well lately. In the 70s stagflation, REITs were second to oil I believe.
REITs... Real-Estate Investment Trusts. Basically a way for you to own rental properties and get a little peice of the pie without actually owning them. Dividends are all 5% or more and they generally stay flat. $HIW $COR $STOR are a few I own instead of letting my money sit around in a bank getting the 0.05% interest.
https://www.google.com/amp/s/www.marketscreener.com/amp/quote/stock/CENTRICUS-ACQUISITION-COR-120780722/news/CENTRICUS-ACQUISITION-CORP-nbsp-Change-in-Directors-or-Principal-Officers-form-8-K-33198479/
Depends on how much alcohol in a given time frame and if your wife or her boyfriend know COR
Upvoting because I love the effort here, but I have to be honest - SWCH is the by far the worst data center player in the entire space. They aren't a REIT because of control structure issues, not because they are trying to avoid paying dividends to retain growth capital. The are absurdly overpaying for Data Foundry (acquisition announced last week) and their investments are highly concentrated in one region In order from most attractive to least attractive, here is how I rank the public data center players based on relative valuation, growth profile, leverage, quality of management, etc 1) CoreSite ($COR), 2) Equinix ($EQIX), 3) Digital Realty ($DLR), 4) QTS ($QTS), 5) CyrusOne ($CONE), and finally 6) Switch ($SWCH)
TEXT: $ADMS - Possible triangle forming here, we also may pull back to $4.50. It is nice here, but if we go red look for that $4.50. $COR - Great horizontal play, I think this is exactly where we want to be. Could be a TAD BIT lower, but this is beautiful. $HZO - Too rich for my blood here, but 5% pull back?! Yea then we are in business - then $HZO becomes an absolute snack. $LEA - We need a small pullback or a 50EMA cross over to be valid. WE in no man's land, we need a value or life here. $LEU - Much the same with $LEU as $LEA. We are a bit too high for value, and a bit low for a confirmation. Give it a day or two. $SITE - Not being dramatic, and it will die because I am going to say this -- probably one of the best technical setups I have seen in weeks. $TBPH - Are we reversing at the dotted trend or the hard trend? I think we have 4 - 5 days to watch this unfold and pick our buy in. $TXN - Did you know the Calculator folks company is worth 165B?! Dang... Well 1% lower it is an absolute snack.
This post mentions: **$GGII** On /r/pennystocks, /u/onegiantbunnie has previously mentioned: ||||||| |:-|:-|:-|:-|:-|:- **ticker**|WKSP|ESS|COR|CETY|BSRC **mentions**|1|1|1|1|1 /u/onegiantbunnie's account was created **5 years ago**. It has **937** comment karma and **175** link karma. ----- ^You ^may ^see ^tickers ^you ^didn't ^mention ^-- ^I'm ^casting ^a ^wide ^net ^because ^y'all ^don't ^always ^$TAG ^your ^ticker ^symbols. ^This ^was ^an ^automated ^response. ^If ^you ^have ^feedback, ^please ^reply ^to ^this ^comment ^or [^(send me a message)](https://www.reddit.com/message/compose?to=RichSteps&subject=bot%20feedback)^.
Healthcare? ABBV, AMGN, MDT Defensive utility? AQN NEE COR reit.
This post mentions: **$CETY, $BSRC** On /r/pennystocks, /u/onegiantbunnie has previously mentioned: ||||| |:-|:-|:-|:- **ticker**|WKSP|ESS|COR **mentions**|1|1|1 /u/onegiantbunnie's account was created **5 years ago**. It has **913** comment karma and **115** link karma. ----- ^You ^may ^see ^tickers ^you ^didn't ^mention ^-- ^I'm ^casting ^a ^wide ^net ^because ^y'all ^don't ^always ^$TAG ^your ^ticker ^symbols. ^This ^was ^an ^automated ^response. ^If ^you ^have ^feedback, ^please ^reply ^to ^this ^comment ^or [^(send me a message)](https://www.reddit.com/message/compose?to=RichSteps&subject=bot%20feedback)^.
This post mentions: **$COR, $ESS, $WKSP** /u/onegiantbunnie's account was created **5 years ago**. It has **780** comment karma and **109** link karma. ----- ^You ^may ^see ^tickers ^you ^didn't ^mention ^-- ^I'm ^casting ^a ^wide ^net ^because ^y'all ^don't ^always ^$TAG ^your ^ticker ^symbols. ^This ^was ^an ^automated ^response. ^If ^you ^have ^feedback, ^please ^reply ^to ^this ^comment ^or [^(send me a message)](https://www.reddit.com/message/compose?to=RichSteps&subject=bot%20feedback)^.
It’s pronounced COR-NELL and it’s the highest rank in the Ivy League
i had a bacon, egg, spinach and blue cheese sandwich with some ethical african coffee. if only i had the brain cells to express the taste any other way than: COR REET BANGIN LA
$SBBP - 1.3m shares recently bought by insiders as opposed to 28k sold and ~60% institutional ownership (reported by NASDAQ). CEO also announced that their drug RECORLEV (COR-003), whose phase 3 data will be presented at the end of this week, showing positive and "statistically significant" results from LOGICS and SONICS studies. They are also attending a virtual conference today I believe.
I agree. I have been adding to AMY and CCI on the dips. I hold DLR and COR too. Any fears of low orbit satellites decreasing the value of towers?
$SBBP is presenting phase 3 data on COR-003 next week, ~70% institutional ownership and recent insider buying.
even though AWS is one of the major players when it comes to hyperscalers, there are other providers out there offering hosting that is eco friendly, totally green and all that shenanigans. datacentres located in norway, sweden.. anywhere where its pretty darn cold and most energy is produced by alternative energies anyway. those are rare though, also they are no hyperscalers and do not offer the same type of services. chaning aws to a completely green footprint will probably not be feasible. I do not think it will hinder them as much. but one can sure hope us humans will see the light one day ;-) side note: there are REIT that concentrate completely on datacenters and such: COR 4.04% Dividend, QTS 3.22% Dividend, CONE 3.11% Dividend DLR 3,33% Dividend EQIX 1,7% Dividend and my personal favorite: IRM, 7.11% Didivend
COR SAIR AND GVME STOP. Why the hell does my comment get deleted when I mention that company? I believe they are both seriously undervalued at this moment in time. Gee Em Ee is about to go through a huge transformation this year, and COR SAIR is seriously undervalued considering its financials.